Table 2.

Univariate analysis of clinicopathological baseline data and IHC markers derived from breast cancer liver metastases and their effect on overall survival (OS after occurrence of liver metastasis)

Parameter	Classification	Distribution	Impact on survival Hazard ratio [95 % CI]	p value (logrank)
Type of surgery	Resection (%)	20.58 % (7/34)	Punch: 3.36 95 % CI [1.14–9.88]	0.0207
	Punch (%)	79.41 % (27/34)
Other distant metastases present at liver metastasis	Yes (%)	44.12 % (15/34)	Present at diagnosis: 1.70 95 % CI [0.80–3.65]	0.1662
	No (%)	55.88 % (19/34)
Chemotherapy (CTx) after diagnosis of liver metastasis	Yes (%)	86.21 % (25/29*)	Yes: 2.21 95 % CI [0.65–7.50]	0.1911
	No (%)	13.79 % (19/29*)
Estrogen receptor (ER)	Positive (%)	55.88 % (19/34)	ER positive: 0.87 95 % CI [0.42–1.80]	0.7003
	Negative (%)	44.12 % (15/34)
Progesterone receptor (PGR)	Positive (%)	32.35 % (11/34)	PR positive: 0.93 95 % CI [0.43–1.99]	0.8428
	Negative (%)	67.65 % (23/34)
Her2/neu	Positive (%)	26.47 % (9/34)	HER2/neu positiv: 1.06 95 % CI [0.45–2.50]	0.8997
	Negative (%)	73.53 % (25/34)
Proliferation index Ki67	Positive (%)	91.18 % (31/34)	Ki67 positive: 2.79 95 % CI [0.65–11.92]	0.1481
	Negative (%)	8.82 % (3/34)
Modified proliferation index Ki67	Positive (%)	52.94 % (18/34)	Ki67 > 30 % positive: 2.46 95 % CI [1.11–5.44]	0.0222
	Negative (%)	47.06 % (16/34)
β-catenin dependent WNT score	High > 1 (%)	44.12 % (15/34)	Wnt-Score high: 0.74 95 % CI [0.35–1.55]	0.4179
	Low ≤ 1 (%)	55.88 % (19/34)
β-catenin independent WNT score	High > 5(%)	64.71 % (22/34)	Wnt-Score high: 2.19 95 % CI [1.02–4.69]	0.0391
	Low ≤ 5 (%)	35.29 % (12/34)

Patient cohort was characterized according to listed parameters in the first column. Type of classification and distribution within the cohort as well as impact on survival including p value (logrank) is given for each parameter

Bold and underlined p-values are meant to highlight those below 0.05

* Cases where not for all patients baseline data was available